USRM (US Stem Cell) Cyclically Adjusted PB Ratio: (As of Jul. 09, 2026)


USRM US Stem Cell Inc USRM
12 GF Score
Price $0.00
View Full Analysis

What is US Stem Cell Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


US Stem Cell  (OTCPK:USRM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


US Stem Cell Cyclically Adjusted PB Ratio Related Terms


US Stem Cell Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for US Stem Cell's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

US Stem Cell Cyclically Adjusted PB Ratio Chart

US Stem Cell Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

US Stem Cell Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

USRM vs NOVNQ, RGRX, NMTRQ: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, US Stem Cell's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


US Stem Cell Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, US Stem Cell's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where US Stem Cell's Cyclically Adjusted PB Ratio falls into.


USRM
12GF Score
US Stem Cell Inc USRM
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

US Stem Cell Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

US Stem Cell's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2022 is calculated as:

For example, US Stem Cell's adjusted Book Value per Share data for the three months ended in Dec. 2022 was:

Adj_Book=Book Value per Share/CPI of Dec. 2022 (Change)*Current CPI (Dec. 2022)
=-0.023/296.7970*296.7970
=-0.023

Current CPI (Dec. 2022) = 296.7970.

US Stem Cell Quarterly Data

Book Value per Share CPI Adj_Book
201303 -73.774 232.773 -94.065
201306 -60.667 233.504 -77.111
201309 -42.856 234.149 -54.322
201312 -36.229 233.049 -46.139
201403 -28.964 236.293 -36.380
201406 -20.570 238.343 -25.615
201409 -20.287 238.031 -25.296
201412 -18.785 234.812 -23.744
201503 -16.249 236.119 -20.425
201506 -11.547 238.638 -14.361
201509 -9.297 237.945 -11.596
201512 -4.480 236.525 -5.622
201603 -2.807 238.132 -3.499
201606 -0.863 241.018 -1.063
201609 -0.300 241.428 -0.369
201612 -0.063 241.432 -0.077
201703 -0.023 243.801 -0.028
201706 -0.021 244.955 -0.025
201709 -0.022 246.819 -0.026
201712 -0.021 246.524 -0.025
201803 -0.018 249.554 -0.021
201806 -0.019 251.989 -0.022
201809 -0.019 252.439 -0.022
201812 -0.018 251.233 -0.021
201903 -0.018 254.202 -0.021
201906 -0.019 256.143 -0.022
201909 -0.023 256.759 -0.027
201912 -0.023 256.974 -0.027
202003 -0.023 258.115 -0.026
202006 -0.024 257.797 -0.028
202009 -0.026 260.280 -0.030
202012 -0.027 260.474 -0.031
202103 -0.025 264.877 -0.028
202106 -0.026 271.696 -0.028
202109 -0.027 274.310 -0.029
202112 -0.025 278.802 -0.027
202203 -0.023 287.504 -0.024
202206 -0.023 296.311 -0.023
202209 -0.022 296.808 -0.022
202212 -0.023 296.797 -0.023

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


US Stem Cell Business Description

Address 1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
12GF Score

Get the complete analysis for USRM

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price